Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + docetaxel
- Development stage
- Phase 2
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of sorafenib, a multikinase inhibitor targeting multiple tyrosine kinases, and docetaxel, a taxane derivative that acts as a mitotic inhibitor. Docetaxel binds to tubulin, promoting assembly and inhibiting disassembly of microtubules, leading to inhibition of cell division and tumor proliferation. Sorafenib inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis. This combination has been studied in various cancer types including gastric cancer, breast cancer, and prostate cancer.
- Brand names
- Nexavar
- Other names
- Docefrez (for docetaxel)
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)BCL-2 (BCL-2 family)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)RK (Ribokinase)RAF1 (c-Raf-1 (Y340D/Y341D))TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sorafenib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + docetaxel.